ReviewNature genetics2026
Mapping the path to clinical implementation of multi-omics.
Review in Nature genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-omics promises to transform medicine by providing holistic disease insights through interacting molecular layers, involving DNA, RNA, proteins and metabolites. The underlying technologies have matured rapidly, currently enabling higher throughputs at lower costs. Yet as multi-omics moves from research to routine care, the central challenge is no longer data generation, but standardizing and interpreting complexity within health systems built for discrete tests. In this Perspective, we chart the path from assay to implementation by demonstrating how integrative analyses outperform single modalities, as well as by emphasizing that multiplexing, high dimensionality and probabilistic interpretation introduce risks to reproducibility and clinical validity. We examine computational strategies for multimodal integration, highlighting the importance of explainable AI for auditability and regulatory trust. Drawing on lessons from early national programs, we suggest that scalable clinical adoption depends on interoperable digital infrastructures, harmonized quality standards and multidisciplinary care models that embed multi-omics into everyday practice.
Indexed as
Identifiers
42414591What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.